Sugammadex versus neostigmine in adults aged 60 years and older undergoing surgery: a systematic review and meta-analysis of postoperative recovery and clinical outcomes
In brief
Sugammadex was linked to 66% less residual paralysis in older surgical patients
Across eight randomized trials involving 851 adults aged 60 and older, sugammadex was associated with a lower risk of residual neuromuscular blockade and about 9 minutes less time in recovery. Apparent reductions in low oxygen levels and hospital stay did not remain statistically significant after an adjusted analysis, and the paralysis finding varied across studies.
- Journal
- Anaesthesia, critical care & pain medicine (Q1)
- Published
- 16 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Edison Vitório de Souza Júnior, Gleisy Kelly Neves Gonçalves, Diego Pires Cruz, Diego Alcântara Alves, Randson Souza Rosa, Namie Okino Sawada
- PMID
- 43039077
- DOI
- 10.1016/j.accpm.2026.101996
Why clinicians should know about it
- Picked for Anesthesiology and Pain Medicine (paper of the day, 19 November 2026): Meta-analysis compares neuromuscular reversal and postoperative recovery outcomes
Abstract
BACKGROUND: Uncertainty remains regarding the clinical advantages of sugammadex over neostigmine in older adults, particularly for recovery efficiency and postoperative outcomes. AIM: To compare the effects of sugammadex versus neostigmine on postoperative recovery and clinical outcomes in adults aged 60 years and older undergoing surgery. METHODS: This systematic review and meta-analysis included eight randomized controlled trials. The primary outcome was postoperative residual neuromuscular blockade (PRNB). Secondary outcomes included post-anesthesia care unit (PACU) length of stay, hospital length of stay, time to extubation, hypoxemia, pneumonia, and postoperative nausea and vomiting (PONV). Effect measures were risk ratio and mean difference. RESULTS: A total of 851 participants were included, and 50.2% received sugammadex. Sugammadex was associated with a lower risk of PRNB (RR 0.34 [95% CI: 0.18; 0.64]; p < 0.001; I² = 54%), with moderate between-study heterogeneity; however, the 95% prediction interval (0.11; 1.03) included the null value. Sugammadex significantly reduced PACU length of stay (MD -8.84 [95% CI: -12.18; -5.51], p < 0.001, I2 = 0%), hospital length of stay (MD -1.12 [95% CI: -2.01; -0.24], p < 0.01, I2 = 16%), and hypoxemia (RR = 0.61 [95% CI: 0.38; 0.97]; p = 0.04, I2 = 0%). No statistically significant differences were observed for the remaining outcomes. CONCLUSION: Sugammadex was associated with a lower risk of PRNB and shorter PACU stays compared with neostigmine. Although the primary analyses suggested reductions in hypoxemia and hospital length of stay, these associations were not statistically significant after the Hartung-Knapp adjustment. INTERNATIONAL PROSPECTIVE REGISTER OF SYSTEMATIC REVIEWS (PROSPERO): CRD420261376045.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.